Medication topics
Mercaptopurine articles covering 6-MP immunomodulator treatment, safety monitoring, combination therapy, and IBD decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
3 articles
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
